World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
113
Citations
70197
World Ranking
4839
National Ranking
2622

Overview

David R. Gandara is affiliated with the University of California, Davis in the United States and has a research focus primarily in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their work spans several subfields, including Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology, and Pathology and Forensic Medicine.

The main topics covered by Gandara's research include Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies, Colorectal Cancer Treatments and Studies, Lung Cancer Diagnosis and Treatment, and Genetic factors in colorectal cancer.

Gandara has contributed to numerous publications, with frequent appearances in key journals such as:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Clinical Lung Cancer
  • Annals of Oncology
  • JCO Precision Oncology

Representative recent papers associated with Gandara's research include:

  • "Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer" (2021), published in Journal of Thoracic Oncology
  • "Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials" (2020), published in Annals of Oncology
  • "Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer" (2023), published in Journal of Clinical Oncology
  • "Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800A" (2022), published in Journal of Clinical Oncology
  • "Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials" (2020), published in Journal of Thoracic Oncology

Frequent coauthors collaborating with Gandara include:

  • Karen Kelly
  • Jonathan W. Riess
  • Mary W. Redman
  • Roy S. Herbst
  • Philip C. Mack

Best Publications

  • Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

    Achim Rittmeyer;Fabrice Barlesi;Daniel Waterkamp;Keunchil Park

  • Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

    Giorgio Vittorio Scagliotti;Purvish Parikh;Joachim von Pawel;Bonne Biesma

  • Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer

    Timothy Winton;Robert Livingston;David H Johnson;James Rigas

  • Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens

    Frank V. Fossella;Russell DeVore;Ronald N. Kerr;Jeffrey Crawford

  • Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

    Naiyer A. Rizvi;Julien Mazières;David Planchard;Thomas E. Stinchcombe

  • Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial

    Karen Kelly;John Crowley;Paul A. Bunn;Cary A. Presant

  • Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

    Kathy S Albain;R Suzanne Swann;Valerie W Rusch;Andrew T Turrisi

  • Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.

    Kathy S. Albain;Valerie W. Rusch;John J. Crowley;Thomas W. Rice

  • Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

    David R. Gandara;Sarah M. Paul;Marcin Kowanetz;Erica Schleifman

  • Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

    Reginald V N Lord;Jan Brabender;David R Gandara;Vicente Alberola

  • Increased Epidermal Growth Factor Receptor Gene Copy Number Detected by Fluorescence In Situ Hybridization Associates With Increased Sensitivity to Gefitinib in Patients With Bronchioloalveolar Carcinoma Subtypes: A Southwest Oncology Group Study

    Fred R. Hirsch;Marileila Varella-Garcia;Jason McCoy;Howard West

  • Proposal for classifying the acute emetogenicity of cancer chemotherapy.

    Paul J. Hesketh;Mark G. Kris;Steven M. Grunberg;Thomas Beck

  • Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study

    Antoinette J. Wozniak;John J. Crowley;Stanley P. Balcerzak;Geoffrey R. Weiss

  • Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023

    Karen Kelly;Kari Chansky;Laurie E. Gaspar;Kathy S. Albain

  • Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

    Agustin A. Garcia;Hal Hirte;Gini Fleming;Dongyun Yang

  • Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.

    Manuel Cobo;Dolores Isla;Bartomeu Massuti;Ana Montes

  • Prospective Evaluation of Cancer Clinical Trial Accrual Patterns: Identifying Potential Barriers to Enrollment

    Primo N. Lara;Roger Higdon;Nelson Lim;Karen Kwan

  • Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

    Leena Gandhi;D. Ross Camidge;Moacyr Ribeiro De Oliveira;Philip Bonomi

  • Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124

    Primo N. Lara;Ronald Natale;John Crowley;Heinz Josef Lenz

  • Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC

    Christian Rolfo;Philip C. Mack;Giorgio V. Scagliotti;Paul Baas

Frequent Co-Authors

Primo N. Lara
Primo N. Lara University of California, Davis
Roy S. Herbst
Roy S. Herbst Yale University
John Crowley
John Crowley Washington University in St. Louis
James H. Doroshow
James H. Doroshow National Institutes of Health
Suresh S. Ramalingam
Suresh S. Ramalingam Emory University
Heinz-Josef Lenz
Heinz-Josef Lenz University of Southern California
Kathy S. Albain
Kathy S. Albain Loyola University Chicago
Everett E. Vokes
Everett E. Vokes University of Chicago
Vassiliki A. Papadimitrakopoulou
Vassiliki A. Papadimitrakopoulou The University of Texas MD Anderson Cancer Center
Laurel A. Beckett
Laurel A. Beckett University of California, Davis

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in medicine doesn’t always mean heading straight for an MD program. There are a variety of related online degrees and specialized pathways to launch or advance your healthcare career. For those seeking to enter the workforce quickly, fast track medical lpn programs offer a streamlined route to becoming a Licensed Practical Nurse, often with flexible schedule options.

If mental health care interests you, consider the growing demand for psychiatric nurse practitioners. Accredited psych np programs online prepare RNs for advanced roles in mental health, opening doors to both clinical and leadership opportunities.

Not all healthcare careers involve direct patient care. Earning a health care administration online degree enables you to work behind the scenes in management and policy development. For those considering advanced leadership, a cheapest online mha program can provide a cost-effective, flexible pathway to upper-level positions.

Whether you are seeking clinical expertise or administrative leadership, these online programs can help you tailor your medical career to your interests, budget, and timeline.

Best Scientists Citing David R. Gandara

Trending Scientists